Modulation of neuropeptide Y receptors for the treatment of obesity

Expert Opinion on Therapeutic Patents

Volumn 19, Issue 10, 2009, Pages 1401-1415

  Sato, Nagaaki ^a,b   Ogino, Yoshio ^b   Mashiko, Satoshi ^b   Ando, Makoto ^b  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Anti obesity; Neuropeptide Y; NPY receptor antagonist agonist; Receptor subtypes

Indexed keywords

1,2,3,4 TETRAHYDROCARBAZOLE DERIVATIVE; 2 [1 (3 CHLORO 5 ISOPROPOXYCARBONYLAMINOPHENYL)ETHYLAMINO] 6 [2 (5 ETHYL 4 METHYL 2 THIAZOLYL)ETHYL] 4 MORPHOLINOPYRIDINE; AMINOPYRIDINE DERIVATIVE; ANTIOBESITY AGENT; BENZAMIDE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; BMS 193885; CARBAZOLE DERIVATIVE; J 104870; MACROGOL; MK 0557; N (1 ACETYL 2,3 DIHYDRO 1H INDOL 6 YL) 3 (3 CYANOPHENYL) N [1 (2 CYCLOPENTYLETHYL) 4 PIPERIDINYL]ACRYLAMIDE; N [2 [1,2 DIHYDRO 3,5(4H) DIOXO 1,2 DIPHENYL 1,2,4 TRIAZOL 4 YL]ETHYL] N2 [[1 [2 [4 [5,11 DIHYDRO 6(6H) OXODIBENZ[B,E]AZEPIN 11 YL] 1 PIPERAZINYL] 2 OXOETHYL]CYCLOPENTYL]ACETYL]ARGININAMIDE; NEUROPEPTIDE Y RECEPTOR; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; NEUROPEPTIDE Y1 RECEPTOR; NEUROPEPTIDE Y2 RECEPTOR; NEUROPEPTIDE Y4 RECEPTOR; NEUROPEPTIDE Y5 RECEPTOR; OBINEPITIDE; PEPTIDE YY [3-36]; PEPTIDE YY[24-36]; PEPTIDE YY[25-36]; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; S 2367; SAR 135966; TM 30335; TM 30339; UNCLASSIFIED DRUG; VELNEPERIT;

CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG WITHDRAWAL; FOOD INTAKE; HUMAN; NAUSEA; NONHUMAN; OBESITY; PATENT; PHARMACOPHORE; REVIEW; STRUCTURE ACTIVITY RELATION; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION;

ANIMALS; ANTI-OBESITY AGENTS; DRUG DESIGN; HUMANS; LIGANDS; MOLECULAR STRUCTURE; NEUROPEPTIDE Y; OBESITY; RECEPTORS, NEUROPEPTIDE Y; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; TREATMENT OUTCOME;

EID: 70349931164     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543770903251722     Document Type: Review

References (127)

1. Haslam DW, James WP. Obesity. Lancet 2005;366:1197-1209
2. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 1992;16:397-415
3. Bray GA, Bellanger T. Epidemiology, trends, and morbidities of obesity and the metabolic syndrome. Endocrine 2006;29:109-117 (Pubitemid 43780352)
4. Barness LA, Opitz JM, Gilbert-Barness E. Obesity: genetic, molecular, and environmental aspects. Am J Med Genet A 2007;143A:3016-3034 (Pubitemid 350274816)
5. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007;369:71-77 • A review of anti-obesity drugs.
6. Halford JC. Pharmacotherapy for obesity. Appetite 2006;46:6-10
7. Rucker D, Padwal R, Li SK, et al. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007;335:1194-1199 (Pubitemid 350273303)
8. Sanofi-Aventis. Available from: http://www.acomplia.com/acl/cx/en/index. jsp [Last accessed 1 June 2009]
9. Wadden TA, Foster GD. Behavioral treatment of obesity. Med Clin North Am 2000;84:441-61, vii
10. Weinsier RL, Hunter GR, Heini AF, et al. The etiology of obesity: relative contribution of metabolic factors, diet, and physical activity. Am J Med 1998;105:145-150
11. Tatemoto K, Carlquist M, Mutt V. Neuropeptide Y - a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature 1982;296:659-660 (Pubitemid 12089070)
12. Stanley BG, Kyrkouli SE, Lampert S, Leibowitz SF. Neuropeptide Y chronically injected into the hypothalamus: a powerful neurochemical inducer of hyperphagia and obesity. Peptides 1986;7:1189-1192 (Pubitemid 17226746)
13. Zarjevski N, Cusin I, Vettor R, et al. Chronic intracerebroventricular neuropeptide-Y administration to normal rats mimics hormonal and metabolic changes of obesity. Endocrinology 1993;133:1753-1758 (Pubitemid 23295205)
14. Sainsbury A, Rohner-Jeanrenaud F, Cusin I, et al. Chronic central neuropeptide Y infusion in normal rats: status of the hypothalamo-pituitary- adrenal axis, and vagal mediation of hyperinsulinaemia. Diabetologia 1997;40:1269-1277 (Pubitemid 27469666)
15. Sanacora G, Kershaw M, Finkelstein JA, White JD. Increased hypothalamic content of preproneuropeptide Y messenger ribonucleic acid in genetically obese Zucker rats and its regulation by food deprivation. Endocrinology 1990;127:730-737 (Pubitemid 20248117)
16. Kesterson RA, Huszar D, Lynch CA, et al. Induction of neuropeptide Y gene expression in the dorsal medial hypothalamic nucleus in two models of the agouti obesity syndrome. Mol Endocrinol 1997;11:630-637 (Pubitemid 27193798)
17. Wilding JP, Gilbey SG, Bailey CJ, et al. Increased neuropeptide-Y messenger ribonucleic acid (mRNA) and decreased neurotensin mRNA in the hypothalamus of the obese (ob/ob) mouse. Endocrinology 1993;132:1939-1944
18. Chua SC Jr, Brown AW, Kim J, et al. Food deprivation and hypothalamic neuropeptide gene expression: effects of strain background and the diabetes mutation. Brain Res Mol Brain Res 1991;11:291-299
19. Guan XM, Yu H, Trumbauer M, et al. Induction of neuropeptide Y expression in dorsomedial hypothalamus of diet-induced obese mice. Neuroreport 1998;9:3415-3419 (Pubitemid 28566122)
20. Blomqvist AG, Herzog H. Y-receptor subtypes - how many more? Trends Neurosci 1997;20:294-298
21. Parker E, Van Heek M, Stamford A. Neuropeptide Y receptors as targets for anti-obesity drug development: perspective and current status. Eur J Pharmacol 2002;440:173-187 (Pubitemid 34458022)
22. Yang K, Guan H, Arany E, et al. Neuropeptide Y is produced in visceral adipose tissue and promotes proliferation of adipocyte precursor cells via the Y1 receptor. FASEB J 2008;22:2452-2464 (Pubitemid 351948663)
23. Pedrazzini T. Importance of NPY Y1 receptor-mediated pathways: assessment using NPY Y1 receptor knockouts. Neuropeptides 2004;38:267-275 (Pubitemid 39158865)
24. Wahlestedt C, Grundemar L, Hakanson R, et al. Neuropeptide Y receptor subtypes, Y1 and Y2. Ann NY Acad Sci 1990;611:7-26
25. Parker RM, Herzog H. Regional distribution of Y-receptor subtype mRNAs in rat brain. Eur J Neurosci 1999;11:1431-1448 (Pubitemid 29142202)
26. Dumont Y, Martel JC, Fournier A, et al. Neuropeptide Y and neuropeptide Y receptor subtypes in brain and peripheral tissues. Prog Neurobiol 1992;38:125-167
27. Goumain M, Voisin T, Lorinet AM, Laburthe M. Identification and distribution of mRNA encoding the Y1, Y2, Y4, and Y5 receptors for peptides of the PP-fold family in the rat intestine and colon. Biochem Biophys Res Commun 1998;247:52-56
28. Tough IR, Holliday ND, Cox HM. Y(4) receptors mediate the inhibitory responses of pancreatic polypeptide in human and mouse colon mucosa. J Pharmacol Exp Ther 2006;319:20-30
29. Gregor P, Millham ML, Feng Y, et al. Cloning and characterization of a novel receptor to pancreatic polypeptide, a member of the neuropeptide Y receptor family. FEBS Lett 1996;381:58-62 (Pubitemid 26071249)
30. Dumont Y, Jacques D, Bouchard P, Quirion R. Species differences in the expression and distribution of the neuropeptide Y Y1, Y2, Y4, and Y5 receptors in rodents, guinea pig, and primates brains. J Comp Neurol 1998;402:372-384
31. Gerald C, Walker MW, Criscione L, et al. A receptor subtype involved in neuropeptide-Y-induced food intake. Nature 1996;382:168-171 (Pubitemid 26242883)
32. Larhammar D, Salaneck E. Molecular evolution of NPY receptor subtypes. Neuropeptides 2004;38:141-151 (Pubitemid 39158855)
33. Mullins D, Kirby D, Hwa J, et al. Identification of potent and selective neuropeptide Y Y(1) receptor agonists with orexigenic activity in vivo. Mol Pharmacol 2001;60:534-540
34. Mashiko S, Ishihara A, Iwaasa H, et al. Characterization of neuropeptide Y (NPY) Y5 receptor-mediated obesity in mice: chronic intracerebroventricular infusion of D-Trp(34)NPY. Endocrinology 2003;144:1793-1801
35. Henry M, Ghibaudi L, Gao J, Hwa JJ. Energy metabolic profile of mice after chronic activation of central NPY Y1, Y2, or Y5 receptors. Obes Res 2005;13:36-47
36. Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002;418:650-654
37. Asakawa A, Inui A, Yuzuriha H, et al. Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology 2003;124:1325-1336 (Pubitemid 36531807)
38. Ishihara A, Moriya M, MacNeil DJ, et al. Neuropeptide Y receptors as targets of obesity treatment. Expert Opin Ther Patents 2006;16:1701-1712 (Pubitemid 46017247)
39. MacNeil DJ. NPYY1 and Y5 receptor selective antagonists as anti-obesity drugs. Curr Top Med Chem 2007;7:1721-1733 (Pubitemid 350131009)
40. Eva C, Serra M, Mele P, et al. Physiology and gene regulation of the brain NPYY1 receptor. Front Neuroendocrinol 2006;27:308-339 (Pubitemid 44548041)
41. Winzell MS, Ahren B. G-protein-coupled receptors and islet function - Implications for treatment of type 2 diabetes. Pharm Ther 2007;116:437-448 (Pubitemid 350116941)
42. Sousa DM, Herzog H, Lamghari M. NPY signalling pathway in bone homeostasis: Y1 Receptor as a Potential Drug Target. Curr Drug Targets 2009;10:9-19
43. Kanatani A, Kanno T, Ishihara A, et al. The novel neuropeptide YY1 receptor antagonist J-104870: A potent feeding suppressant with oral bioavailability. Biochem Biophys Res Commun 1999;266:88-91 (Pubitemid 30028772)
44. Kanatani A, Hata M, Mashiko S, et al. A typical y1 receptor regulates feeding behaviors: effects of a potent and selective Y1 antagonist, J-115814. Mol Pharmacol 2001;59:501-505 (Pubitemid 32179929)
45. Ishihara A, Kanatani A, Okada M, et al. Blockade of body weight gain and plasma corticosterone levels in Zucker fatty rats using an orally active neuropeptide YY1 antagonist. Br J Pharmacol 2002;136:341-346 (Pubitemid 34620513)
46. Antal-Zimanyi I, Bruce MA, LeBoulluec KL, et al. Pharmacological characterization and appetite suppressive properties of BMS-193885, a novel and selective neuropeptide Y-1 receptor antagonist. Eur J Pharmacol 2008;590:224-232
47. Cerep. NPY antagonists, preparation and use. WO2006108965; 2006
48. Cerep. Compounds based on four aromatic rings, preparation and uses thereof. WO2007071840; 2007
49. Di Fabio R, Giovannini R, Bertani B, et al. Synthesis and SAR of substituted tetrahydrocarbazole derivatives as new NPY-1 antagonists. Bioorg Med Chem Lett 2006;16:1749-1752 (Pubitemid 43197559)
50. Leslie CP, Di Fabio R, Bonetti F, et al. Novel carbazole derivatives as NPY y1 antagonists. Bioorg Med Chem Lett 2007;17:1043-1046 (Pubitemid 46177611)
51. Kameda M, Kobayashi K, Ito H, et al. Optimization of a series of 2,4-diaminopyridines as neuropeptide Y Y1 receptor antagonists with reduced hERG activity. Bioorg Med Chem Lett 2009;19:4325-4329
52. Colmers WF, Klapstein GJ, Fournier A, et al. Presynaptic inhibition by neuropeptide Y in rat hippocampal slice in vitro is mediated by a Y2 receptor. Br J Pharmacol 1991;102:41-44
53. Silva AP, Carvalho AP, Carvalho CM, Malva JO. Modulation of intracellular calcium changes and glutamate release by neuropeptide Y1 and Y2 receptors in the rat hippocampus: differential effects in CA1, CA3 and dentate gyrus. J Neurochem 2001;79:286-296
54. Chen X, DiMaggio DA, Han SP, Westfall TC. Autoreceptor-induced inhibition of neuropeptide Y release from PC-12 cells is mediated by Y2 receptors. Am J Physiol 1997;273:H1737-44 (Pubitemid 27479272)
55. King PJ, Williams G, Doods H, Widdowson PS. Effect of a selective neuropeptide Y Y(2) receptor antagonist, BIIE0246 on neuropeptide Y release. Eur J Pharmacol 2000;396:R1-3
56. Smith-White MA, Hardy TA, Brock JA, Potter EK. Effects of a selective neuropeptide Y Y2 receptor antagonist, BIIE0246, on Y2 receptors at peripheral neuroeffector junctions. Br J Pharmacol 2001;132:861-868
57. Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003;349:941-948 (Pubitemid 37064767)
58. Reidelberger RD, Haver AC, Chelikani PK, Buescher JL. Effects of different intermittent peptide YY (3-36) dosing strategies on food intake, body weight, and adiposity in diet-induced obese rats. Am J Physiol Regul Integr Comp Physiol 2008;295:R449-58
59. Chelikani PK, Haver AC, Reidelberger RD. Intermittent intraperitoneal infusion of peptide YY(3-36) reduces daily food intake and adiposity in obese rats. Am J Physiol Regul Integr Comp Physiol 2007;293:R39-46
60. Vrang N, Madsen AN, Tang-Christensen M, et al. PYY(3-36) reduces food intake and body weight and improves insulin sensitivity in rodent models of diet-induced obesity. Am J Physiol Regul Integr Comp Physiol 2006;291:R367-75
61. Pittner RA, Moore CX, Bhavsar SP, et al. Effects of PYY[3-36] in rodent models of diabetes and obesity. Int J Obes Relat Metab Disord 2004;28:963-971
62. Boey D, Lin S, Karl T, et al. Peptide YY ablation in mice leads to the development of hyperinsulinaemia and obesity. Diabetologia 2006;49:1360-1370
63. Boey D, Lin S, Enriquez RF, et al. PYY transgenic mice are protected against diet-induced and genetic obesity. Neuropeptides 2008;42:19-30
64. Talsania T, Anini Y, Siu S, et al. Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology 2005;146:3748-3756
65. Gura T. Obesity research. Labs fail to reproduce protein's appetite-suppressing effects. Science 2004;305:158-159
66. Tschop M, Castaneda TR, Joost HG, et al. Physiology: does gut hormone PYY3-36 decrease food intake in rodents? Nature 2004;430:1
67. DeCarr LB, Buckholz TM, Milardo LF, et al. A long-acting selective neuropeptide Y2 receptor PEGylated peptide agonist reduces food intake in mice. Bioorg Med Chem Lett 2007;17:1916-1919 (Pubitemid 46367681)
68. Bayer Pharmaceuticals Corporation. Selective neuropeptide Y2 receptor agonists. WO2005053726; 2005
69. Bayer Pharmaceuticals Corporation. Selective neuropeptide Y2 receptor agonists. WO2006049681; 2006
70. DeCarr LB, Buckholz TM, Coish PDG, et al. Identification of selective neuropeptide Y2 peptide agonists. Bioorg Med Chem Lett 2007;17:538-541
71. Lumb KJ, DeCarr LB, Milardo LF, et al. Novel selective neuropeptide Y2 receptor PEGylated peptide agonists reduce food intake and body weight in mice. J Med Chem 2007;50:2264-2268 (Pubitemid 46683081)
72. 7TM Pharma A/S. Y2 selective receptor agonists for therapeutic interventions. WO2005089789; 2005
73. 7TM Pharma A/S. Y2/Y4 selective receptor agonists for therapeutic interventions. WO2005089790; 2005
74. 7TM Pharma A/S. Y2 selective receptor agonists for therapeutic interventions. WO2007038943; 2007
75. Meeting report: Obesity Drug Development - CBI's Third Annual Summit, Arlington, VA, USA, 26-27 July 2007
76. 7TM Pharma pipeline (2009). Available from: http://www.7tm.com/Pipeline. aspx [Last accessed 1 June 2009] • First clinical report of a Y2/Y4 dual agonist.
77. Kuo LE, Kitlinska JB, Tilan JU, et al. Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med 2007;13:803-811
78. Gantz I, Erondu N, Mallick M, et al. Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. J Clin Endocrinol Metab 2007;92:1754-1757 • POC clinical trial of PYY3-36. (Pubitemid 46997183)
79. Schwartz TW. Pancreatic polypeptide: a hormone under vagal control. Gastroenterology 1983;85:1411-1425
80. Fox JA. Control of gastrointestinal motility by peptides: old peptides, new tricks - new peptides, old tricks. Gastroenterol Clin North Am 1989;18:163-177
81. McLaughlin CL, Baile CA. Obese mice and the satiety effects of cholecystokinin, bombesin and pancreatic polypeptide. Physiol Behav 1981;26:433-437 (Pubitemid 11124998)
82. Taylor IL, Garcia R. Effects of pancreatic polypeptide, caerulein, and bombesin on satiety in obese mice. Am J Physiol 1985;248:G277-80 (Pubitemid 15077809)
83. Malaisse-Lagae F, Carpentier JL, Patel YC, et al. Pancreatic polypeptide: a possible role in the regulation of food intake in the mouse. Hypothesis. Experientia 1977;33:915-917 (Pubitemid 8128835)
84. Gates RJ, Lazarus NR. The ability of pancreatic polypeptides (APP and BPP) to return to normal the hyperglycaemia, hyperinsulinaemia and weight gain of New Zealand obese mice. Horm Res 1977;8:189-202
85. Ueno N, Inui A, Iwamoto M, et al. Decreased food intake and body weight in pancreatic polypeptide overexpressing mice. Gastroenterology 2000;118:1239
86. Berntson GG, Zipf WB, O'Dorisio TM, et al. Pancreatic polypeptide infusions reduce food intake in Prader-Willi syndrome. Peptides 1993;14:497-503 (Pubitemid 23186716)
87. Batterham RL, Le Roux CW, Cohen MA, et al. Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab 2003;88:3989-3992 (Pubitemid 37034556)
88. Jesudason DR, Monteiro MP, McGowan BM, et al. Low-dose pancreatic polypeptide inhibits food intake in man. Br J Nutr 2007;97:426-429
89. Lieverse RJ, Masclee AA, Jansen JB, Lamers CB. Plasma cholecystokinin and pancreatic polypeptide secretion in response to bombesin, meal ingestion and modified sham feeding in lean and obese persons. Int J Obes Relat Metab Disord 1994;18:123-127
90. Uhe AM, Szmukler GI, Collier GR, et al. Potential regulators of feeding behavior in anorexia nervosa. Am J Clin Nutr 1992;55:28-32
91. Balasubramaniam A, Mullins DE, Lin S, et al. Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar affinity. J Med Chem 2006;49:2661-2665
92. Bayer Pharmaceuticals Corporation. Neuropeptide Y4 receptor agonists. WO2006091506; 2006
93. 7TM Pharma A/S. Y4 selective receptor agonists for therapeutic interventions. WO2005089786; 2005
94. 7TM Pharma A/S. Y4 selective receptor agonists for therapeutic interventions. WO2007038942; 2007
95. 7TM Pharma A/S. Y-receptor agonists. WO2008132435; 2008
96. Andres CJ, Zimanyi IA, Deshpande MS, et al. Differentially functionalized diamines as novel ligands for the NPY2 receptor. Bioorg Med Chem Lett 2003;13:2883-2885
97. Janssen Pharmaceutica N.V. Indole or quinoline derivatives as non-pepticid NPY Y2 receptor inhibitors useful for the treatment of anxiolytic and depressive disorders and obesity. WO2005030754; 2005
98. Jablonowski JA, Chai WY, Li XB, et al. Novel non-peptidic neuropeptide YY2 receptor antagonists. Bioorg Med Chem Lett 2004;14:1239-1242 (Pubitemid 38229864)
99. Mark Seierstad: small-molecule Y2 receptor antagonists: identification of a novel and potent series using pharmacophore-based virtual screening. [abstract MEDI-045] 234th ACS National Meeting, Boston, MA, United States, 2007 August 19-23; 2009
100. Janssen Pharmaceutica N.V. Substituted piperazines and piperidines as modulators of the neuropeptide Y2 receptor. WO2007053436; 2007
101. Bonaventure P, Nepomuceno D, Mazur C, et al. Characterization of N-(1-acetyl-2,3-dihydro-1H-indol-6-yl)-3-(3-cyano-phenyl)-N-[1-(2-cyclop entyl-ethyl)-piperidin-4yl]-acrylamide (JNJ-5207787), a small molecule antagonist of the neuropeptide YY2 receptor. J Pharmacol Exp Ther 2004;308:1130-1137 (Pubitemid 38263990)
102. Janssen Pharmaceutica N.V. Piperazinyl derivatives useful as modulators of the neuropeptide Y2 receptor. WO2009006185; 2009
103. Novartis ag/orain david/nozulak joachim. Organic compounds. WO2009050201A2; 2009
104. Novartis ag/nozulak joachim/orain david. Imidazolidine-2,4-dione (hydantoin) derivatives useful as npy y2 receptor modulators. WO2009050200A1; 2009
105. Novartis ag/nozulak joachim/orain david/cotesta simona. Organic compounds. WO2009050197A2; 2009
106. Erondu N, Gantz I, Musser B, et al. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metabolism 2006;4:275-282 •• Clinical results with MK-0557. (Pubitemid 44430911)
107. Erondu N, Wadden T, Gantz I, et al. Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight loss. Obesity 2007;15:895-905 •• Clinical results with MK-0557. (Pubitemid 46740965)
108. Shionogi & Co., Ltd. website news release (2009). Available from: http://www.shionogi.co.jp/ir-en/news/detail/e-090217-2.pdf [Last accessed 1 June 2009]
109. Shionogi & Co., Ltd. NPYY5 antagonists. WO2001037826; 2001
110. Banyu Pharmaceutical Co., Ltd. Novel spiro compounds. WO2001014376; 2001
111. Takahashi T, Haga Y, Sakamoto T, et al. Aryl urea derivatives of spiropiperidines as NPY Y5 receptor antagonists. Bioorg Med Chem Lett. In Press, Corrected Proof
112. Sakamoto T, Moriya M, Haga Y, et al. Identification of novel and orally active spiroindoline NPY Y5 receptor antagonists. Bioorg Med Chem Lett 2009;19:1564-1568
113. Mashiko S, Ishihara A, Iwaasa H, et al. Effects of a novel Y5 antagonist in obese mice: Combination with food restriction or sibutramine. Obesity 2008;16:1510-1515 (Pubitemid 351915099)
114. Glaxo Group Ltd. 1-Oxa-3-azaspiro (4.5) decan-2-one and 1-oxa-3, 8-diazaspiro (4.5) decan-2-one derivatives for the treatment of eating disorders. WO2008092887; 2008
115. Glaxo Group Ltd. 1-oxa-3-azaspiro[4,5] decan--2-one derivatives for the treatment of eating disorders. WO2008092888A1; 2008
116. Glaxo Group Ltd. 1-Oxa-3-azaspiro(45) decan-2-one derivatives for the treatment of eating disorders. WO2008092891; 2008
117. Guba W, Neidhart W, Nettekoven M. Novel and potent NPY5 receptor antagonists derived from virtual screening and iterative parallel chemistry design. Bioorg Med Chem Lett 2005;15:1599-1603 (Pubitemid 40312537)
118. Nettekoven M, Guba W, Neidhart W, et al. Isomeric thiazole derivatives as ligands for the neuropeptide Y5 receptor. Bioorg Med Chem Lett 2005;15:3446-3449 •• Clinical results with velneperit (S-2367). (Pubitemid 40835753)
119. None. Thiazole derivatives. US20050038089; 2005
120. None. Thiazole derivatives. US20050038073; 2005
121. Glaxo Group Limited. Benzimidazoles with a hetero spiro-decane residue as NPY-Y5 antagonists. WO2008129007; 2008
122. Neurogen Corporation. Spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3h-spiroisobenzofuran-1, 4′-piperidines. WO2002048152; 2002
123. Banyu Pharmaceutical Co., Ltd. Novel benzimidazole derivatives. WO2004002986; 2004
124. Kanatani A, Mashiko S, Murai N, et al. Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: Comparison of wild-type, Y1 receptor-deficient, and Y5 receptor-deficient mice. Endocrinology 2000;141:1011-1016
125. Lin EJD, Sainsbury A, Lee NJ, et al. Combined deletion of Y1, Y2, and Y4 receptors prevents hypothalamic neuropeptide Y overexpression-induced hyperinsulinemia despite persistence of hyperphagia and obesity. Endocrinology 2006;147:5094-5101
126. Mashiko S, Moriya R, Ishihara A, et al. Synergistic interaction between neuropeptide Y Y1 and Y5 receptor pathways in regulation of energy homeostasis. Eur J Pharmacol 2009;615:113-117
127. Moriya R, Mashiko S, Ishihara A, et al. Comparison of independent and combined chronic anti-obese effects of NPY Y2 receptor agonist, PYY(3-36), and NPY Y5 receptor antagonist in diet-induced obese mice. Peptides 2009;30:1318-1322